Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-0ee00d4506e3873c8f0ac45771449e6f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-0ee00d4506e3873c8f0ac45771449e6f",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-0ee00d4506e3873c8f0ac45771449e6f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-0ee00d4506e3873c8f0ac45771449e6f\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-0ee00d4506e3873c8f0ac45771449e6f</b></p><a name=\"composition-en-0ee00d4506e3873c8f0ac45771449e6f\"> </a><a name=\"hccomposition-en-0ee00d4506e3873c8f0ac45771449e6f\"> </a><a name=\"composition-en-0ee00d4506e3873c8f0ac45771449e6f-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1052/001 14 film-coated tablets</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - edistride</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/15/1052/001 14 film-coated tablets"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp0ee00d4506e3873c8f0ac45771449e6f"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - edistride",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Edistride is and what it is used for</li><li>What you need to know before you take Edistride</li><li>How to take Edistride</li><li>Possible side effects</li><li>How to store Edistride</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What edistride is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What edistride is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Edistride is Edistride contains the active substance dapagliflozin. It belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors . They work by blocking the SGLT2 protein in your kidney. By blocking this protein, blood sugar (glucose), salt (sodium) and water are removed from your body via the urine. What Edistride is used for Edistride is used to treat:</p><h2 id=\"type-2-diabetes\">Type 2 diabetes</h2><h2 id=\"in-adults-and-children-aged-10-years-and-older\">in adults and children aged 10 years and older.</h2><h2 id=\"if-your-type-2-diabetes-cannot-be-controlled-with-diet-and-exercise\">if your type 2 diabetes cannot be controlled with diet and exercise.</h2><h2 id=\"edistride-can-be-used-on-its-own-or-together-with-other-medicines-to-treat-diabetes\">Edistride can be used on its own or together with other medicines to treat diabetes.</h2><p>It is important to continue to follow the advice on diet and exercise given to you by your doctor, pharmacist or nurse.</p><h2 id=\"heart-failure\">Heart failure</h2><p>in adults (aged 18 years and older) when the heart does not pump blood as well as it should.</p><h2 id=\"chronic-kidney-disease\">Chronic kidney disease</h2><p>in adults with reduced kidney function. What is type 2 diabetes and how does Edistride help?</p><p>In type 2 diabetes your body does not make enough insulin or is not able to use the insulin it makes properly. This leads to a high level of sugar in your blood. This can lead to serious problems like heart or kidney disease, blindness, and poor circulation in your arms and legs.</p><p>Edistride works by removing excess sugar from your body. It can also help prevent heart disease. What is heart failure and how does Edistride help?</p><p>This type of heart failure occurs when the heart does not pump blood to the lungs and the rest of the body as well as it should. This can lead to serious medical problems and need for hospital care.</p><p>The most common symptoms of heart failure are feeling breathless, feeling tired or very tired all the time, and ankle swelling.</p><p>Edistride helps protect your heart from getting worse and improves your symptoms. It can lower the need to go to hospital and can help some patients to live longer. What is chronic kidney disease and how does Edistride help?</p><p>When you have chronic kidney disease, your kidneys may gradually lose their function. This means they would not be able to clean and filter your blood the way they should. Loss of kidney function can lead to serious medical problems and need for hospital care.</p><p>Edistride helps protect your kidneys from losing their function. That can help some patients to live longer.</p></div>"
}
},
{
"title" : "2. What you need to know before you take edistride",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take edistride"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Edistride</p><p>if you are allergic to dapagliflozin or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Contact a doctor or the nearest hospital straight away Diabetic ketoacidosis:</p><p>If you have diabetes and experience feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat or rapid weight loss.</p><p>The above symptoms could be a sign of diabetic ketoacidosis a rare but serious, sometimes life-threatening problem you can get with diabetes because of increased levels of ketone bodies in your urine or blood, seen in tests.</p><p>The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.</p><p>When you are treated with Edistride, diabetic ketoacidosis can occur even if your blood sugar is normal. If you suspect you have diabetic ketoacidosis, contact a doctor or the nearest hospital straight away and do not take this medicine. Necrotising fasciitis of the perineum:</p><p>Talk to your doctor immediately if you develop a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus with fever or feeling generally unwell. These symptoms could be a sign of a rare but serious or even life-threatening infection, called necrotising fasciitis of the perineum or Fournier s gangrene which destroys the tissue under the skin. Fournier s gangrene has to be treated immediately. Talk to your doctor, pharmacist or nurse before taking Edistride</p><p>if you have type 1 diabetes the type that usually starts when you are young, and your body does not produce any insulin. Edistride should not be used to treat this condition.</p><p>if you have diabetes and have a kidney problem your doctor may ask you to take additional or a different medicine to control your blood sugar.</p><p>if you have a liver problem your doctor may start you on a lower dose.</p><p>if you are on medicines to lower your blood pressure (anti-hypertensives) and have a history of low blood pressure (hypotension). More information is given below under Other medicines and Edistride .</p><p>if you have very high levels of sugar in your blood which may make you dehydrated (lose too much body fluid). Possible signs of dehydration are listed in section 4. Tell your doctor before you start taking Edistride if you have any of these signs.</p><p>if you have or develop nausea (feeling sick), vomiting or fever or if you are not able to eat or drink. These conditions can cause dehydration. Your doctor may ask you to stop taking Edistride until you recover to prevent dehydration.</p><p>if you often get infections of the urinary tract. This medicine may cause urinary tract infections and your doctor may want to monitor you more closely. Your doctor may consider temporarily changing your treatment if you develop a serious infection. If any of the above applies to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Edistride. Diabetes and foot care If you have diabetes, it is important to check your feet regularly and adhere to any other advice regarding foot care given by your health care professional. Urine glucose Because of how Edistride works, your urine will test positive for sugar while you are on this medicine. Elderly ( 65 years and above) If you are elderly, there may be a higher risk that your kidneys function less well and that you are treated with other medicines (see also Kidney function above and Other medicines and Edistride<br/>below). Children and adolescents Edistride can be used in children aged 10 years and older for the treatment of type 2 diabetes. No data are available in children below 10 years of age. Edistride is not recommended for children and adolescents under 18 years of age for the treatment of heart failure or for the treatment of chronic kidney disease, because it has not been studied in these patients. Other medicines and Edistride Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Especially tell your doctor:</p><p>if you are taking a medicine used to remove water from the body (diuretic).</p><p>if you are taking other medicines that lower the amount of sugar in your blood such as insulin or a sulphonylurea medicine. Your doctor may want to lower the dose of these other medicines, to prevent you from getting low blood sugar levels (hypoglycaemia).</p><p>if you are taking lithium because Edistride can lower the amount of lithium in your blood. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should stop taking this medicine if you become pregnant, since it is not recommended during the second and third trimesters of pregnancy. Talk to your doctor about the best way to control your blood sugar while you are pregnant. Talk to your doctor if you would like to or are breast-feeding before taking this medicine. Do not use Edistride if you are breast-feeding. It is not known if this medicine passes into human breast milk. Driving and using machines Edistride has no or negligible influence on the ability to drive and use machines. Taking this medicine with other medicines called sulphonylureas or with insulin can cause too low blood sugar levels (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines. Do not drive or use any tools or machines, if you feel dizzy taking Edistride. Edistride contains lactose Edistride contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p></div>"
}
},
{
"title" : "3. How to take edistride",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take edistride"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure. How much to take</p><p>The recommended dose is one 10 mg tablet each day.</p><p>Your doctor may start you on a 5 mg dose if you have a liver problem.</p><p>Your doctor will prescribe the strength that is right for you. Taking this medicine</p><p>Swallow the tablet whole with half a glass of water.</p><p>You can take your tablet with or without food.</p><p>You can take the tablet at any time of the day. However, try to take it at the same time each day. This will help you to remember to take it. Your doctor may prescribe Edistride together with other medicine(s). Remember to take these other medicine(s) as your doctor has told you. This will help get the best results for your health. Diet and exercise can help your body use its blood sugar better. If you have diabetes, it is important to stay on any diet and exercise program recommended by your doctor while taking Edistride. If you take more Edistride than you should If you take more Edistride tablets than you should, talk to a doctor or go to a hospital immediately. Take the medicine pack with you. If you forget to take Edistride What to do if you forget to take a tablet depends on how long it is until your next dose.</p><p>If it is 12 hours or more until your next dose, take a dose of Edistride as soon as you remember. Then take your next dose at the usual time.</p><p>If it is less than 12 hours until your next dose, skip the missed dose. Then take your next dose at the usual time.</p><p>Do not take a double dose of Edistride to make up for a forgotten dose. If you stop taking Edistride Do not stop taking Edistride without talking to your doctor first. If you have diabetes, your blood sugar may increase without this medicine. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact a doctor or the nearest hospital straight away if you have any of the following side effects:</p><p>angioedema, seen very rarely (may affect up to 1 in 10,000 people). These are signs of angioedema:</p><ul><li>swelling of the face, tongue or throat</li><li>difficulties swallowing</li><li>hives and breathing problems</li></ul><p>diabetic ketoacidosis - this is rare in patients with type 2 diabetes (may affect up to 1 in 1,000 people). These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions):</p><ul><li>increased levels of ketone bodies in your urine or blood</li><li>feeling sick or being sick</li><li>stomach pain</li><li>excessive thirst</li><li>fast and deep breathing</li><li>confusion</li><li>unusual sleepiness or tiredness</li><li>a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat</li><li>rapid weight loss. This may occur regardless of blood sugar level. Your doctor may decide to temporarily or permanently stop your treatment with Edistride.</li></ul><p>necrotising fasciitis of the perineum or Fournier s gangrene, a serious soft tissue infection of the genitals or the area between the genitals and the anus, seen very rarely. Stop taking Edistride and see a doctor as soon as possible if you notice any of the following serious side effects:</p><p>urinary tract infection, seen commonly (may affect up to 1 in 10 people). These are signs of a severe infection of the urinary tract:</p><ul><li>fever and/or chills</li><li>burning sensation when passing water (urinating)</li><li>pain in your back or side. Although uncommon, if you see blood in your urine, tell your doctor immediately. Contact your doctor as soon as possible if you have any of the following side effects:</li></ul><p>low blood sugar levels (hypoglycaemia), seen very commonly (may affect more than 1 in 10 people) in patients with diabetes taking this medicine with a sulphonylurea or insulin. These are the signs of low blood sugar:</p><ul><li>shaking, sweating, feeling very anxious, fast heart beat</li><li>feeling hungry, headache, change in vision</li><li>a change in your mood or feeling confused. Your doctor will tell you how to treat low blood sugar levels and what to do if you get any of the signs above. Other side effects when taking Edistride: Common</li></ul><p>genital infection (thrush) of your penis or vagina (signs may include irritation, itching, unusual discharge or odour)</p><p>back pain</p><p>discomfort when passing water (urine), passing more water than usual or needing to pass water more often</p><p>changes in the amount of cholesterol or fats in your blood (shown in tests)</p><p>increases in the amount of red blood cells in your blood (shown in tests)</p><p>decreases in creatinine renal clearance (shown in tests) in the beginning of treatment</p><p>dizziness</p><p>rash Uncommon (may affect up to 1 in 100 people)</p><p>fungal infection</p><p>loss of too much fluid from your body (dehydration, signs may include very dry or sticky mouth, passing little or no urine or fast heartbeat)</p><p>thirst</p><p>constipation</p><p>awakening from sleep at night to pass urine</p><p>dry mouth</p><p>weight decreased</p><p>increases in creatinine (shown in laboratory blood tests) in the beginning of treatment</p><p>increases in urea (shown in laboratory blood tests) Very rare</p><p>inflammation of the kidneys (tubulointerstitial nephritis) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store edistride",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store edistride"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date, which is stated on the blister or carton after EXP . The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Edistride contains</p><p>The active substance is dapagliflozin. Each Edistride 5 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin. Each Edistride 10 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 10 mg dapagliflozin.</p><p>The other ingredients are:</p><p>tablet core: microcrystalline cellulose (E460i), lactose (see section 2 Edistride contains lactose ), crospovidone (E1202), silicon dioxide (E551), magnesium stearate (E470b).</p><p>film-coating: poly(vinyl alcohol) (E1203), titanium dioxide (E171), macrogol (3350) (E1521), talc (E553b), yellow iron oxide (E172). What Edistride looks like and contents of the pack Edistride 5 mg film-coated tablets are yellow and round with diameter of 0.7 cm. They have 5 on one side and 1427 on the other side. Edistride 10 mg film-coated tablets are yellow and diamond-shaped approximately 1.1 x 0.8 cm diagonally. They have 10 on one side and 1428 on the other side. Edistride 5 mg tablets and Edistride 10 mg tablets are available in aluminium blisters in pack sizes of 14, 28 or 98 film-coated tablets in non-perforated calendar blisters and 30x1 or 90x1 film-coated tablets in perforated unit dose blisters. Not all pack sizes may be marketed in your country. Marketing Authorisation Holder AstraZeneca AB SE-151 85 S dert lje Sweden Manufacturer AstraZeneca AB G rtunav gen SE-152 57 S dert lje Sweden AstraZeneca UK Limited Silk Road Business Park Macclesfield SK10 2NA United Kingdom For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 Lietuva UAB AstraZeneca Lietuva Tel: +370 5 2660</p><p>.: +359 (2) 44 55 Luxembourg/Luxemburg AstraZeneca S.A./N.V. T l/Tel: +32 2 370 48 esk republika AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 Magyarorsz g AstraZeneca Kft. Tel.: +36 1 883 6Danmark AstraZeneca A/S Tlf: +45 43 66 64 Malta Associated Drug Co. Ltd Tel: +356 2277 8Deutschland AstraZeneca GmbH Tel: +49 40 809034Nederland AstraZeneca BV Tel: +31 85 808 9Eesti AstraZeneca Tel: +372 6549 Norge AstraZeneca AS Tlf: +47 21 00 64<br/>sterreich AstraZeneca A.E. : +30 2 106871AstraZeneca sterreich GmbH Tel: +43 1 711 31 0 Espa a Esteve Pharmaceuticals, S.A. Tel: +34 93 446 60 Laboratorio Tau, S. A. Tel: +34 91 301 91 Polska AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 France AstraZeneca T l: +33 1 41 29 40 Portugal BIAL-Portela & C ., S.A. Tel.: +351 22 986 61 Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 Rom nia AstraZeneca Pharma SRL Tel: +40 21 317 60 Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7Slovenija AstraZeneca UK Limited Tel: +386 1 51 35 sland Vistor hf. S mi: +354 535 7Slovensk republika AstraZeneca AB, o.z. Tel: +421 2 5737 7Italia AstraZeneca S.p.A. Tel: +39 02 00704Suomi/Finland AstraZeneca Oy Puh/Tel: +358 10 23</p><p>: +357 22490Sverige AstraZeneca AB Tel: +46 8 553 26 Latvija SIA AstraZeneca Latvija Tel: +371 67377United Kingdom (Northern Ireland) AstraZeneca UK Ltd Tel: +44 1582 836 This leaflet was last revised in Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp0ee00d4506e3873c8f0ac45771449e6f",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp0ee00d4506e3873c8f0ac45771449e6f",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp0ee00d4506e3873c8f0ac45771449e6f\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp0ee00d4506e3873c8f0ac45771449e6f</b></p><a name=\"mp0ee00d4506e3873c8f0ac45771449e6f\"> </a><a name=\"hcmp0ee00d4506e3873c8f0ac45771449e6f\"> </a><a name=\"mp0ee00d4506e3873c8f0ac45771449e6f-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1052/001 14 film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Edistride 5 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/15/1052/001 14 film-coated tablets"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Edistride 5 mg film-coated tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
